• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

全腮腺切除术后美学与功能并发症的管理。首次使用 Surgimend® 真皮基质治疗腮腺恶性肿瘤患者的长期经验。

Management of Aesthetical and Functional Complications after Total Parotidectomy. First Long-Term Experiences with Dermal Matrix Surgimend ® in Patient Affected by Malignant Parotid Tumors.

作者信息

Bonavolonta Paola, Iaconetta Giorgio, Improda Giovanni, Germano Cristiana, Borriello Gerardo, Goglia Federica, Abbate Vincenzo, Piombino Pasquale, Califano Luigi, Dell'Aversana Orabona Giovanni

机构信息

Maxillofacial Surgery UnitDepartmentof Medicine and SurgeryDepartment of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II, Via Sergio Pansini 5, 80131 Naples, Italy.

Department of Neurosurgery, University of Salerno, Salerno, Italy.

出版信息

J Maxillofac Oral Surg. 2024 Dec;23(6):1535-1541. doi: 10.1007/s12663-022-01761-y. Epub 2022 Jul 23.

DOI:10.1007/s12663-022-01761-y
PMID:39618453
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11607226/
Abstract

BACKGROUND

This is an observational cohort study on patients affected by malignant parotid tumors treated with total parotidectomy. The aim of our work is to analyze and compare the effects and complications after parotidectomy, using or not SurgiMend ®.

METHODS

40 patients were retrospectively enrolled between September 2014 and June 2020. Basing on the placement of SurgiMend ® for parotid lodge reconstruction, the samples were divided into two groups. Thus, the incidence rate of complications after the surgical procedure was analyzed between the two groups.

RESULTS

Patients in whom SurgiMend ® was used reported a lower rate of complications The ANOVA test ( = 0.05) revealed a significant difference of Vancouver Scar Scale (VSS) between the two groups, representation as vascularity and pigmentation improvement, changing scar color, scar height reduction, and increased pliability.

CONCLUSION

Although many techniques are available to fill the parotidectomy defect, improve facial contour and prevent Frey's syndrome, the use of SurgiMend ® matrix is one of most effective and reliable method to address these complications, with the advantage of decreased operative time due to not require an additional surgical donor site.

摘要

背景

这是一项关于接受全腮腺切除术治疗的腮腺恶性肿瘤患者的观察性队列研究。我们研究的目的是分析和比较使用或不使用SurgiMend®进行腮腺切除术后的效果和并发症。

方法

回顾性纳入2014年9月至2020年6月期间的40例患者。根据是否使用SurgiMend®进行腮腺窝重建将样本分为两组。因此，分析了两组手术并发症的发生率。

结果

使用SurgiMend®的患者并发症发生率较低。方差分析（P = 0.05）显示两组之间温哥华瘢痕量表（VSS）存在显著差异，表现为血管化和色素沉着改善、瘢痕颜色改变、瘢痕高度降低和柔韧性增加。

结论

尽管有许多技术可用于填补腮腺切除术后的缺损、改善面部轮廓和预防Frey综合征，但使用SurgiMend®基质是解决这些并发症最有效和可靠的方法之一，其优点是无需额外的手术供区，从而缩短了手术时间。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e71/11607226/6310e71ad29a/12663_2022_1761_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e71/11607226/4b9a306427d7/12663_2022_1761_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e71/11607226/6310e71ad29a/12663_2022_1761_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e71/11607226/4b9a306427d7/12663_2022_1761_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e71/11607226/6310e71ad29a/12663_2022_1761_Fig2_HTML.jpg

相似文献

1
Management of Aesthetical and Functional Complications after Total Parotidectomy. First Long-Term Experiences with Dermal Matrix Surgimend ® in Patient Affected by Malignant Parotid Tumors.全腮腺切除术后美学与功能并发症的管理。首次使用 Surgimend® 真皮基质治疗腮腺恶性肿瘤患者的长期经验。
J Maxillofac Oral Surg. 2024 Dec;23(6):1535-1541. doi: 10.1007/s12663-022-01761-y. Epub 2022 Jul 23.
2
Graft interposition for preventing Frey's syndrome in patients undergoing parotidectomy.在腮腺切除术患者中植入移植物以预防味觉出汗综合征
Cochrane Database Syst Rev. 2019 Oct 3;10(10):CD012323. doi: 10.1002/14651858.CD012323.pub2.
3
Effect of human acellular dermal matrix (Megaderm™) on infra-auricular depressed deformities, Frey's syndrome, and first bite syndrome following parotidectomy: a multi-center prospective study.人脱细胞真皮基质（Megaderm™）对腮腺切除术后耳下凹陷畸形、味觉出汗综合征及第一口综合征的影响：一项多中心前瞻性研究。
Gland Surg. 2021 Feb;10(2):670-677. doi: 10.21037/gs-20-703.
4
Acellular dermal matrix (Insuregraf) in the prevention of Frey's syndrome and surgical site depression after parotidectomy.脱细胞真皮基质（Insuregraf）在预防腮腺切除术后Frey综合征及手术部位凹陷中的应用
Arch Craniofac Surg. 2019 Jun;20(3):176-180. doi: 10.7181/acfs.2019.00248. Epub 2019 Jun 20.
5
Prospective outcomes following drainless superficial parotidectomy with sternocleidomastoid flap reconstruction.无引流腮腺浅叶切除术联合胸锁乳突肌皮瓣重建术的前瞻性结果。
J Otolaryngol Head Neck Surg. 2020 Oct 6;49(1):72. doi: 10.1186/s40463-020-00472-z.
6
Selective Deep Lobe Parotidectomy vs Total Parotidectomy for Patients With Benign Deep Lobe Parotid Tumors.选择性腮腺深叶切除术与腮腺全切除术治疗腮腺良性深叶肿瘤的对比研究。
JAMA Otolaryngol Head Neck Surg. 2023 Nov 1;149(11):1003-1010. doi: 10.1001/jamaoto.2023.2981.
7
Mitigating complications rate in parotid gland tumor surgery by reconstruction technique with SurgiMend®: a retrospective, single-center, observational study on 300 consecutive patients.使用SurgiMend®重建技术降低腮腺肿瘤手术并发症发生率：一项对300例连续患者的回顾性、单中心观察性研究。
J Craniomaxillofac Surg. 2025 Aug;53(8):1129-1134. doi: 10.1016/j.jcms.2025.04.012. Epub 2025 May 4.
8
Autologous Free Dermal-Fat-Fascial Graft for Parotidectomy Defects: A Case Series.自体游离真皮脂肪筋膜瓣修复腮腺切除术后缺损：病例系列研究。
Ann Otol Rhinol Laryngol. 2021 Oct;130(10):1171-1180. doi: 10.1177/0003489421999542. Epub 2021 Mar 4.
9
Acellular dermal matrix for prevention of Frey's syndrome after superficial parotidectomy of benign tumors.脱细胞真皮基质预防良性肿瘤腮腺浅叶切除术后 Frey 综合征。
Am J Otolaryngol. 2021 Mar-Apr;42(2):102893. doi: 10.1016/j.amjoto.2020.102893. Epub 2021 Jan 4.
10
Efficacy of SMAS flap technique to prevent Frey's syndrome and aesthetic outcomes. A retrospective cohort analysis.SMAS 皮瓣技术预防弗雷氏综合征和美学效果的疗效。回顾性队列分析。
Ann Ital Chir. 2021;92:683-690.

本文引用的文献

1
Prognostic factors in parotid cancers: Clinicopathological and treatment factors influencing outcomes.腮腺癌的预后因素：影响预后的临床病理及治疗因素
Indian J Cancer. 2018 Jan-Mar;55(1):98-104. doi: 10.4103/ijc.IJC_503_17.
2
Complications after parotid gland surgery Our experience.腮腺手术后的并发症 我们的经验
Ann Ital Chir. 2017;88:295-301.
3
Use of the SMAS flap for reconstruction of the parotid lodge.使用SMAS瓣重建腮腺区。
Acta Otorhinolaryngol Ital. 2015 Dec;35(6):406-11. doi: 10.14639/0392-100X-395.
4
Use of dermis-fat grafts in the prevention of Frey's syndrome after parotidectomy.在腮腺切除术后使用真皮脂肪移植预防味觉出汗综合征。
J Craniomaxillofac Surg. 2016 Mar;44(3):301-8. doi: 10.1016/j.jcms.2015.12.007. Epub 2015 Dec 23.
5
Effects of free fat grafting on the prevention of Frey's syndrome and facial depression after parotidectomy: A prospective randomized trial.游离脂肪移植对腮腺切除术后预防味觉出汗综合征和面部凹陷的效果：一项前瞻性随机试验。
Laryngoscope. 2016 Apr;126(4):815-9. doi: 10.1002/lary.25714. Epub 2015 Oct 9.
6
Paraumbilical fat graft for the correction of contour deformity following parotidectomy and prevention of Frey syndrome.脐旁脂肪移植用于腮腺切除术后轮廓畸形的矫正及预防味觉出汗综合征。
Int J Oral Maxillofac Surg. 2016 Mar;45(3):380-2. doi: 10.1016/j.ijom.2015.07.017. Epub 2015 Oct 4.
7
What score on the Vancouver Scar Scale constitutes a hypertrophic scar? Results from a survey of North American burn-care providers.温哥华瘢痕量表的多少分算作增生性瘢痕？北美烧伤护理提供者调查的结果。
Burns. 2015 Nov;41(7):1442-8. doi: 10.1016/j.burns.2015.04.018. Epub 2015 Jul 2.
8
Bovine versus Porcine Acellular Dermal Matrix: A Comparison of Mechanical Properties.牛脱细胞真皮基质与猪脱细胞真皮基质：力学性能比较
Plast Reconstr Surg Glob Open. 2014 Jun 6;2(5):e155. doi: 10.1097/GOX.0000000000000072. eCollection 2014 May.
9
Reconstructive techniques of the parotid region.腮腺区的重建技术。
J Craniofac Surg. 2014 May;25(3):998-1002. doi: 10.1097/SCS.0000000000000664.
10
A modified Vancouver Scar Scale linked with TBSA (mVSS-TBSA): Inter-rater reliability of an innovative burn scar assessment method.改良温哥华瘢痕量表结合体表面积（mVSS-TBSA）：一种创新烧伤瘢痕评估方法的组内信度。
Burns. 2013 Sep;39(6):1142-9. doi: 10.1016/j.burns.2013.01.014. Epub 2013 Feb 22.